Preparation, characterization, and anticancer efficacy of evodiamine-loaded PLGA nanoparticles

Abstract Evodiamine (EVO) is a plant-derived indolequinazoline alkaloid with potential anticancer activity. However, low bioavailability caused by its poor water solubility limits it anticancer efficacy in clinic. To enhance the solubility and improve the bioavailability of EVO, a delivery system based on poly (lactic-co-glycolic acid) (PLGA) nanoparticles loaded with EVO (EVO-PLGA NPs) for treating breast cancer was prepared in this study. The physicochemical characterization and in vitro antitumor evaluation of EVO-PLGA NPs were determined. EVO-PLGA NPs could persistently control the release of EVO for 180 h. 3-[4,5-Dimethyl-2-thiazolyl]-2,5-diphenyl tetrazolium bromide (MTT) assessment and colony formation assay showed that EVO-PLGA NPs could enhance the toxicity and the proliferation inhibition effect of EVO on MCF-7 breast cancer cells. EVO-PLGA NPs did not strengthen G2/M arrest effect of EVO-treated cells after 24h incubation. Meanwhile, EVO-PLGA NPs could increase the expression of cyclin B1 and decrease the expression of β-actin. Taken together, these results suggested that -PLGA NPs is promising for improving anticancer efficacy of EVO in breast cancer therapy.

[1]  C. Teng,et al.  Induction of mitotic arrest and apoptosis by evodiamine in human leukemic T-lymphocytes. , 2004, Life sciences.

[2]  Dai Li,et al.  Transdermal behaviors comparisons among Evodia rutaecarpa extracts with different purity of evodiamine and rutaecarpine and the effect of topical formulation in vivo. , 2012, Fitoterapia.

[3]  S. Sahoo,et al.  PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. , 2011, Advanced drug delivery reviews.

[4]  Anderson,et al.  Biodegradation and biocompatibility of PLA and PLGA microspheres. , 1997, Advanced drug delivery reviews.

[5]  V. Beral,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[6]  Lie-Chwen Lin,et al.  Anti‐Proliferative Effects of Evodiamine on Human Thyroid Cancer Cell Line ARO , 2010, Journal of cellular biochemistry.

[7]  T. Ikejima,et al.  Evodiamine, a constituent of Evodiae Fructus, induces anti‐proliferating effects in tumor cells , 2003, Cancer science.

[8]  Muhammad Khan,et al.  Cytotoxic effect of evodiamine in SGC-7901 human gastric adenocarcinoma cells via simultaneous induction of apoptosis and autophagy. , 2012, Oncology reports.

[9]  Jun Peng,et al.  Pharmacokinetic comparisons of rutaecarpine and evodiamine after oral administration of Wu-Chu-Yu extracts with different purities to rats. , 2012, Journal of ethnopharmacology.

[10]  Qiang Z Yu,et al.  Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells. , 2013, Cancer letters.

[11]  Luciana Facco Dalmolin,et al.  Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. , 2013, Colloids and surfaces. B, Biointerfaces.

[12]  J. Ervasti,et al.  β-Actin specifically controls cell growth, migration, and the G-actin pool , 2011, Molecular biology of the cell.

[13]  Ick Chan Kwon,et al.  The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[14]  M. Li‐Weber,et al.  Targeting apoptosis pathways in cancer by Chinese medicine. , 2013, Cancer letters.

[15]  C. Teng,et al.  Induction of mitotic arrest and apoptosis in human prostate cancer pc-3 cells by evodiamine. , 2005, The Journal of urology.

[16]  Jun-Lin Jiang,et al.  Evodiamine: A Novel Anti-Cancer Alkaloid from Evodia rutaecarpa , 2009, Molecules.

[17]  Vladimir Torchilin,et al.  Tumor delivery of macromolecular drugs based on the EPR effect. , 2011, Advanced drug delivery reviews.

[18]  R. Kobayashi,et al.  Phosphorylation and activation of 13S condensin by Cdc2 in vitro. , 1998, Science.

[19]  B. Aggarwal,et al.  Evodiamine Abolishes Constitutive and Inducible NF-κB Activation by Inhibiting IκBα Kinase Activation, Thereby Suppressing NF-κB-regulated Antiapoptotic and Metastatic Gene Expression, Up-regulating Apoptosis, and Inhibiting Invasion* , 2005, Journal of Biological Chemistry.

[20]  J. Cooper,et al.  Effects of cytochalasin and phalloidin on actin , 1987, The Journal of cell biology.

[21]  J. Vishwanatha,et al.  Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. , 2009, Anticancer research.

[22]  Olivier Rouaud,et al.  Microencapsulation by solvent evaporation: state of the art for process engineering approaches. , 2008, International journal of pharmaceutics.

[23]  S. Gray,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[24]  Xiu-feng Wang,et al.  Evodiamine induces apoptosis and inhibits metastasis in MDA‑MB-231 human breast cancer cells in vitro and in vivo. , 2013, Oncology reports.

[25]  V. Préat,et al.  PLGA-based nanoparticles: an overview of biomedical applications. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[26]  Shengzheng Wang,et al.  New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations. , 2012, Journal of medicinal chemistry.

[27]  P. Chumakov,et al.  Disruption of actin microfilaments by cytochalasin D leads to activation of p53 , 1998, FEBS letters.

[28]  B. Chazotte.  Labeling cytoskeletal F-actin with rhodamine phalloidin or fluorescein phalloidin for imaging. , 2010, Cold Spring Harbor protocols.

[29]  Hongwei Jin,et al.  Pharmacological Actions of Multi-Target-Directed Evodiamine , 2013, Molecules.

[30]  Mingjun Wu,et al.  Design and Evaluation of a Novel Evodiamine-Phospholipid Complex for Improved Oral Bioavailability , 2012, AAPS PharmSciTech.

[31]  Alicia Fernandez-Fernandez,et al.  Preparation and characterization of a polymeric (PLGA) nanoparticulate drug delivery system with simultaneous incorporation of chemotherapeutic and thermo-optical agents. , 2010, Colloids and surfaces. B, Biointerfaces.